Endor Nanotechnologies R&D develops medical applications using inorganic nanoparticles conjugated to biological active molecules. Inorganic nanoparticles offer a versatile platform with wide technological possibilities for the development of new treatments, drug delivery and diagnostic systems. The last decade has seen the advent of the first generation of companies around the world devoted to applying these nanoparticles in medical applications. Endor forms part of this generation.

The R&D Department is the main driving force at Endor Nanotechnologies. All R&D initiatives are fully aligned with the company business development and finance perspective.

R&D expertise is 100% focused on designing medical applications with advanced inorganic nanosystems. Currently, the R&D department is divided in two associated divisions: Nanomaterials and Pharmacology.

Endor’s expertise using new nanomaterials for biomedical applications is focused on the development of our leading medical program, the EDS. Our multidisciplinary R&D team is constantly growing and it is associated with many senior collaborators and advisors in the field.